How many clinicians do I need to interview for meaningful VOC research?

For exploratory VOC (needs-finding), most medtech programs look for pattern saturation: the point at which new interviews are confirming patterns already identified rather than introducing new themes. In practice, that often occurs between fifteen and thirty interviews for a well-defined clinical setting. For concept validation VOC, smaller numbers can be sufficient if the participants are carefully selected to represent the target use environment. There is no universal sample size standard for qualitative VOC research in medtech.

Do I need IRB approval for VOC interviews?

It depends on the specific activities and how they are conducted. Qualitative interviews with clinicians about their professional experience with existing procedures and tools typically do not require IRB review, because they do not involve human subjects research as defined by 45 CFR Part 46 (https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46). However, if VOC activities involve patient contact, patient data, identifiable protected health information, or evaluation of an investigational device, IRB review may be required. Your regulatory counsel should make this determination for your specific research design.

What is the difference between a KOL advisory board and a clinical advisory board?

The terms are often used interchangeably in the industry. In practice, Key Opinion Leader advisory board tends to emphasize commercial influence: these are clinicians whose adoption of a device influences peers. Clinical advisory board tends to emphasize technical input: these are clinicians who provide expertise on clinical study design, device performance requirements, and clinical use cases. Many medtech companies have panels that serve both functions.

Can I use VOC interview quotes in my marketing materials?

Clinician testimonials and case studies can be used in marketing materials, with appropriate consent, attribution, and compliance with disclosure requirements where the clinician has a financial relationship with the company. Testimonial claims are subject to the same regulatory requirements as any other device claim: they must be consistent with the cleared or approved indications for use and must not constitute promotion for off-label uses. The FDA's guidance on the use of real-world evidence and patient-reported outcomes is an evolving area; consult regulatory counsel before publishing clinical testimonials.

How does VOC research differ from clinical user testing under FDA human factors guidance?

Formative usability testing and summative human factors validation studies (conducted under the FDA's Human Factors guidance, https://www.fda.gov/media/80481/download) are distinct regulatory activities from commercial VOC research. Human factors studies evaluate whether users can use the device safely and effectively, using defined representative-use scenarios and a specific methodology. VOC research evaluates what users want from a device and how they make decisions about adoption. Both generate user input, but for different purposes and under different frameworks. Many companies conduct both.

Should I conduct VOC research before or after building a prototype?

Both, at different stages. Exploratory VOC (Stage 1) should happen before any prototype is built, because the goal is to understand the clinical problem without anchoring to a specific solution. Concept VOC (Stage 2) can include prototype evaluation, but the prototype at this stage should be low-fidelity enough that clinicians feel free to suggest fundamental changes without feeling they are discarding finished work. High-fidelity prototypes too early in VOC tend to anchor feedback to incremental modifications rather than surfacing fundamental need gaps.

Voice of Customer Research for Medical Devices: How to Get the Surgeon and Clinician Input That Actually Shapes Your Product

Direct answer: Voice of Customer (VOC) research in medical devices is the structured process of gathering direct input from surgeons, clinicians, nurses, patients, and hospital buyers to understand what problems they actually face, what performance they require in a solution, and what would drive adoption of a new device. VOC in medtech differs from consumer VOC because clinical practice, regulatory labeling requirements, and multi-stakeholder procurement decisions all shape what "the customer wants" means. The output of a well-run VOC program is a prioritized set of user needs and performance requirements that drives both product development and go-to-market strategy. (As of July 2026.)

Medical device companies that skip structured VOC research do not save time. They spend it differently: revising designs after the design transfer, scrambling at the pre-launch stage to explain a product that solves a problem surgeons did not know they had, or discovering during a pivotal trial that the clinical endpoint they powered the study around is not the one physicians actually care about.

VOC is not optional in a well-run device development program. It is the foundation of the requirements that drive engineering, the evidence base that informs regulatory claims, and the source material for the marketing positioning that communicates your device's value to buyers, clinicians, and payers.

What VOC Research Means in Medical Devices

In consumer goods or B2B SaaS, VOC often means survey data, NPS scores, and interview panels with buyers. In medtech, the concept is the same but the stakeholder structure is more complex.

The device's "customers" in a clinical context include at least four groups with distinct priorities.

Clinicians (primary users). Surgeons, interventionalists, anesthesiologists, or specialist physicians who will use the device in clinical practice. Their needs center on clinical performance: does the device work reliably, does it improve or maintain patient outcomes, does it fit into the workflow without adding procedural risk, and does it perform better than what they already use?

Nurses and allied health professionals. Scrub nurses, cath lab technicians, and OR techs interact with devices throughout the procedure. Their needs often center on setup, sterilization, ergonomics, and the practical details of device handling that the surgeon may not notice.

Hospital procurement and value analysis committees. These are the institutional buyers. Their needs center on cost, demonstrated clinical value, reimbursement adequacy, and vendor reliability. A device that surgeons love can fail commercially if it cannot pass a value analysis committee.

Patients. Patients experience the outcomes of device use, the recovery burden, and the quality-of-life implications of the procedure. Patient-reported outcomes are increasingly important in both regulatory submissions and reimbursement decisions. The FDA has advanced patient-reported and patient-preference information in the device context through its patient science and CDRH patient-engagement work, in parallel with the better-known Patient-Focused Drug Development program on the drug side.

Effective VOC in medtech captures input from all four groups, not just the surgeon.

The Three Stages of Medtech VOC

VOC research in medical devices is not a single survey or a one-time focus group. It is an iterative process that evolves as the device concept matures. The three stages correspond to different development phases.

Stage 1: Exploratory VOC (pre-development). The goal is to understand the clinical problem in its full context before any solution is proposed. This is the needs-finding phase described in the Biodesign process (https://biodesign.stanford.edu/our-work/biodesign-process/identify/needs-finding-and-needs-screening.html). Conversations are open-ended and observational. The researcher is listening for problems, frustrations, workarounds, and unmet performance expectations. No solution is pitched. No features are evaluated.

Stage 2: Concept VOC (early development). Once a concept direction is established, VOC shifts to evaluating whether the proposed solution addresses the identified needs. This stage uses more structured interviews and can include early prototype evaluation, concept boards, or use scenario presentations. The goal is to confirm that the solution approach matches the identified needs and to identify design features that require iteration.

Stage 3: Validation VOC (late development/pre-launch). Before a device goes to market, VOC confirms that the device as built meets the needs that were identified in early research, that the positioning and messaging resonate with the intended audience, and that the sales and training materials adequately communicate the device's value to the full buyer chain. This stage also generates the commercial evidence (representative clinician feedback, key opinion leader endorsements, publication strategies) that supports the go-to-market program.

How to Structure Clinician Interviews

The interview is the primary VOC tool in medical devices. A well-structured interview generates specific, actionable input. A poorly structured one generates vague enthusiasm that cannot be used to make engineering or commercial decisions.

Preparation. Review the peer-reviewed literature on the target procedure and its complications. Watch recorded procedure videos if available. Talk to any clinical advisors before the formal interview series. The goal is to arrive at interviews knowledgeable enough to ask precise follow-up questions, not knowledgeable enough to already know the answers.

Participant selection. Recruit participants who represent the intended clinical use environment: the specialty, the procedure volume, the practice setting (academic vs. community), and the geography. Include high-volume practitioners who see the problem at its most acute, and include lower-volume practitioners who reflect the commercial majority of device users. Include skeptics, not just enthusiasts.

Interview structure. A medtech VOC interview for exploratory research typically runs 45 to 60 minutes and covers three areas: current clinical experience with the problem (open-ended, problem-focused), frustrations and limitations with current solutions (specific and probing), and performance requirements for an ideal solution (without proposing one). Concept VOC interviews add a fourth area: reaction to specific solution approaches.

Question design. Open-ended questions produce more useful data than yes/no questions. "Tell me about the most difficult part of this procedure" generates a richer response than "Is tissue visualization a problem during this procedure?" The goal is to get the clinician talking about their experience, not confirming your hypothesis.

Documentation and synthesis. Record interviews (with participant consent), transcribe, and code responses thematically. Synthesize across participants to identify patterns: needs that appear repeatedly across multiple clinicians, performance thresholds that come up consistently, and adoption barriers that are mentioned independently by multiple respondents.

Building a Key Opinion Leader (KOL) Advisory Panel

A KOL advisory panel is a structured relationship with a small group of clinicians who provide ongoing input into device development, clinical study design, publication strategy, and commercial launch preparation. It is a formal extension of VOC research.

KOL panels in medtech serve several distinct functions: they provide clinical validation of the product concept, they help design the clinical study that will support regulatory submission and commercial claims, they author or co-author the publications that establish the clinical evidence base, and they serve as credible third-party voices in the commercial launch program.

Panel composition. A meaningful KOL panel typically includes three to ten clinicians across different institution types and geographies. Include recognized academic leaders in the target specialty who carry peer influence; include high-volume community practitioners who reflect real-world adoption patterns; include one or two international clinicians if the commercial strategy includes global markets.

Conflict of interest management. KOL relationships must be structured to manage conflicts of interest appropriately. Compensation should be fair market value for the time spent on legitimate advisory activities, documented in a consulting agreement. The relationship must be disclosed in any publications the KOL co-authors. Companies working in this area should ensure their KOL engagement practices are consistent with the OIG compliance guidance for pharmaceutical manufacturers (https://oig.hhs.gov/compliance/compliance-guidance/index.asp), which the medical device industry generally treats as a reference point, and with the AdvaMed Code of Ethics on Interactions with Health Care Professionals (https://www.advamed.org/resource/advamed-code-of-ethics/), which is the industry self-regulatory standard. These relationships, structured and conducted appropriately, are normal and expected parts of medical device development.

What VOC Research Cannot Tell You

VOC research produces qualitative and quantitative input from a selected group of clinicians. It has real limitations that the research design should account for.

Stated preferences are not the same as actual adoption decisions. Clinicians who say they would use a device in VOC interviews and clinicians who actually change their practice when the device is available are different populations. The gap between stated intent and actual behavior is well-documented in adoption research across healthcare. VOC should be treated as directional evidence, not a guarantee of adoption.

KOL enthusiasm is not market representation. A high-volume academic surgeon at a major medical center may hold views that differ significantly from the community surgeon who accounts for 80% of the procedure volume. VOC programs should explicitly seek input from the commercial majority, not just the most accessible clinical experts.

VOC does not replace clinical evidence. The clinical evidence required for regulatory submission and for claims in marketing materials comes from controlled clinical studies, not from VOC interviews. VOC informs the clinical study design by identifying the endpoints that matter to clinicians. It does not replace the study.

How VOC Connects to Marketing and Regulatory Claims

VOC research has a direct connection to both the regulatory submission and the marketing program that is often underestimated.

Regulatory connection. The performance requirements that emerge from VOC research inform the device's intended use and indications for use, which are reviewed by the FDA in the 510(k) or PMA submission. VOC research can also identify the clinical endpoint that a pivotal study should use, which directly affects whether the trial generates data sufficient to support the intended marketing claims. If VOC research identifies that surgeons care most about a specific performance metric, the clinical study should be designed to measure that metric.

Marketing connection. The language clinicians use to describe their problems and their performance expectations is the most effective source material for marketing claims. Clinician testimonials, advisory board endorsements, and published clinical feedback are the third-party validation elements that move hospital procurement decisions. The specific problems VOC identified become the value proposition language in your product literature, sales training, and conference presentations.

This is the connection Buzzbox Media has built its medtech content practice around: grounding marketing claims in the clinical evidence, needs-finding data, and VOC research the product team has already gathered. Companies that engage marketing strategists at the VOC stage (not at the launch stage) produce more precise, more defensible positioning than those who build the marketing story after the fact.

If you want to talk through how your VOC research connects to positioning, clinical communication, and go-to-market strategy, a 30-minute call is available at https://www.buzzboxmedia.com/book.